» Articles » PMID: 36686835

Contribution of Natural Killer Cells in Innate Immunity Against Colorectal Cancer

Overview
Journal Front Oncol
Specialty Oncology
Date 2023 Jan 23
PMID 36686835
Authors
Affiliations
Soon will be listed here.
Abstract

Natural killer cells are members of the innate immune system and promote cytotoxic activity against tumor or infected cells independently from MHC recognition. NK cells are modulated by the expression of activator/inhibitory receptors. The ratio of this activator/inhibitory receptors is responsible for the cytotoxic activity of NK cells toward the target cells. Owing to the potent anti-tumor properties of NK cells, they are considered as interesting approach in tumor treatment. Colorectal cancer (CRC) is the second most common cause of death in the world and the incidence is about 2 million new cases per year. Metastatic CRC is accompanied by a poor prognosis with less than three years of overall survival. Chemotherapy and surgery are the most adopted treatments. Besides, targeted therapy and immune checkpoint blockade are novel approach to CRC treatment. In these patients, circulating NK cells are a prognostic marker. The main target of CRC immune cell therapy is to improve the tumor cell's recognition and elimination by immune cells. Adaptive NK cell therapy is the milestone to achieve the purpose. Allogeneic NK cell therapy has been widely investigated within clinical trials. In this review, we focus on the NK related approaches including CAR NK cells, cell-based vaccines, monoclonal antibodies and immunomodulatory drugs against CRC tumoral cells.

Citing Articles

Prognostic significance of perioperative circulating CD56 NK cell and recovery of NK cell activity in patients with colorectal cancer undergoing radical surgery.

You J, Lee C, Lee Y, Chern Y, Liao C, Hsu H Transl Oncol. 2024; 52():102198.

PMID: 39657310 PMC: 11683267. DOI: 10.1016/j.tranon.2024.102198.


CAR-NK Cell Therapy: A Transformative Approach to Overcoming Oncological Challenges.

Li W, Wang X, Zhang X, Aziz A, Wang D Biomolecules. 2024; 14(8).

PMID: 39199421 PMC: 11352442. DOI: 10.3390/biom14081035.


Promotes the Proliferation and Migration of Tumor Cells and Predicts Poor Prognosis in Colorectal Cancer.

Zhang S, Huang L, Zeng Y, Gao G, Wu H, Li D ACS Omega. 2024; 9(19):21116-21126.

PMID: 38764627 PMC: 11097367. DOI: 10.1021/acsomega.4c00901.


Therapeutic Anti-KIR Antibody of 1-7F9 Attenuates the Antitumor Effects of Expanded and Activated Human Primary Natural Killer Cells on In Vitro Glioblastoma-like Cells and Orthotopic Tumors Derived Therefrom.

Maeoka R, Nakazawa T, Matsuda R, Morimoto T, Shida Y, Yamada S Int J Mol Sci. 2023; 24(18).

PMID: 37762486 PMC: 10531877. DOI: 10.3390/ijms241814183.

References
1.
Deschaseaux F, Delgado D, Pistoia V, Giuliani M, Morandi F, Durrbach A . HLA-G in organ transplantation: towards clinical applications. Cell Mol Life Sci. 2010; 68(3):397-404. PMC: 11114658. DOI: 10.1007/s00018-010-0581-6. View

2.
Sun Y, Sedgwick A, Palarasah Y, Mangiola S, Barrow A . A Transcriptional Signature of PDGF-DD Activated Natural Killer Cells Predicts More Favorable Prognosis in Low-Grade Glioma. Front Immunol. 2021; 12:668391. PMC: 8444979. DOI: 10.3389/fimmu.2021.668391. View

3.
De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D Andrea M . Genetic diversity of the KIR/HLA system and outcome of patients with metastatic colorectal cancer treated with chemotherapy. PLoS One. 2014; 9(1):e84940. PMC: 3908861. DOI: 10.1371/journal.pone.0084940. View

4.
Grzywacz B, Kataria N, Verneris M . CD56(dim)CD16(+) NK cells downregulate CD16 following target cell induced activation of matrix metalloproteinases. Leukemia. 2007; 21(2):356-9. DOI: 10.1038/sj.leu.2404499. View

5.
Reddy N, Hernandez-Ilizaliturri F, Deeb G, Roth M, Vaughn M, Knight J . Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2007; 140(1):36-45. DOI: 10.1111/j.1365-2141.2007.06841.x. View